Facet browsing currently unavailable
Page 1 of 1 results
Sort by: relevance publication year
Showing DOI matching
10.1093/annonc/mdx816
S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial JOURNAL ARTICLE published March 2018 in Annals of Oncology |